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investigate which parameters were related to the patients‘ 
opinion about cosmesis. In addition, we analyzed whether 
firmness, presence of rib pain or quality of life (QoL) aspects 
(EORTC QLQ C-30 questionnaire) at 4 years were related to 
the patients’ opinion on cosmetic outcome.  
 
Results: Of the 7 BCCT.core parameters, pBCE and pBCD 
were significantly related to patients’ score at 4 years. 
Patients with any difference in firmness rated their cosmesis 
worse than patients without any difference, even when the 
objective score (i.e. BCCT.core) was similar. This effect was 
larger by increasing difference. Worse perception of cosmetic 
outcome was also independently related to lower global QoL, 
lower emotional functioning and higher scores in the 
depression scale. The presence of rib pain had no influence. 
 
Conclusion: The patients‘ opinion on cosmetic outcome was 
significantly related to objective parameters like distance 
from nipple to inframammary fold (pBCE) and length of 
breast contour (pBCD), but also to subjective factors, i.e. 
severity of firmness, depressive feelings, global QoL and 
emotional functioning. 
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Purpose or Objective: The primary endpoint of this phase II 
study was to determine the progression-free survival (PFS) of 
oligometastatic breast cancer patients treated with radical 
radiotherapy to all metastatic sites. 
 
Material and Methods: Patients affected by oligometastatic 
breast cancer were enrolled in this phase II trial. Inclusion 
criteria were the following: 1) histologically confirmed 
diagnosis of breast cancer, 2) 5 or fewer metastatic lesions, 
3) no brain metastases, 4) primary tumor controlled. 
Radiotherapeutic treatment was SBRT (30-45 Gy in 3 
fractions) or fractionated IMRT (40-60 Gy in 15-25 fractions). 
Primary endpoint was PFS; secondary endpoints were local-
control (LC), overall survival (OS), and toxicity, which was 
assessed using the CTCAE v4.0 scale. 
 
Results: The analysis was conducted on 37 patients. The 
median age was 55 years. Twenty-five (68%) had 
oligometastatic disease at diagnosis, and 12 (32%) had the 
oligometastatic status induced by systemic treatment. 
Sixteen (43%) patients had a single metastasis, and 21 (47%) 
had 2 or more lesions. Thirty-one (84%) patients were treated 
with SBRT and 6 (16%) with fractionated IMRT. With a median 
follow-up of 18 months, 1-year and 2-year PFS was 74% and 
44%, respectively. No differences was seen in PFS between 
patients with only 1 metastases vs. those with ≥2 metastases, 
or between patients treated with SBRT vs. fractionated IMRT. 
Only two patients experienced local failure. One of these two 
patients had an isolated local failure for a spinal lesion that 
was treated with a minimum dose of 17 Gy in 3 fractions 
(being the spinal cord constraint prior on the PTV coverage). 
Two-year LC was 96%. Two patients died of disease, and 2-
year OS was 96%. The proposed treatment was well 
tolerated; no Grade ≥3 toxicity was documented. Two 
patients experienced Grade 2 pain, 4 Grade 1 pain, and 2 
developed Grade 2 fatigue. 
 
Conclusion: Radical radiotherapy delivered to all the 
metastatic sites in oligometastatic breast cancer patients led 
to promising results in terms of local control and progression-
free survival. Treatment was well tolerated. The results of 
this study may motivate for conducting phase III trials. 
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Purpose or Objective: Previous studies have shown an 
increased risk of ischemic heart disease in breast cancer 
patients treated with radiotherapy (RT). It has recently been 
reported that the risk of major coronary events increases per 
gray of mean radiation dose delivered to the heart for 
patients undergoing either left- or right-sided breast RT. 
However, the anatomy of cardiovascular damage related to 
right-sided breast RT has not been well-described, 
specifically for radiation dose delivered to the right coronary 
artery (RCA). This may be of particular relevance for regional 
nodal irradiation that includes the internal mammary nodes 
(IMNs). In this prospective planning study, the impact of IMN 
irradiation on the RCA and organs at risk (OAR) in patients 
undergoing right-sided post-mastectomy RT (PMRT) was 
assessed. 
 
Material and Methods: CT simulation scans of 60 right-sided 
post-mastectomy patients were identified from an 
institutional database. In 30 cases, the IMNs were contoured 
from the 1st to 3rd intercostal space with a PTV of 5 mm. 
The RCA, heart, lungs and contralateral breast were 
delineated as OARs. A four-field modified wide tangent 
photon plan was created encompassing the chestwall, IMNs, 
supraclavicular fossa and axilla. For the remaining 30 
patients (control group), a four-field plan that excluded the 
IMNs was generated. All patients were planned to receive 50 
Gy in 25 fractions over 5 weeks. Doses were compared 
between the two groups utilizing the Mann-Whitney test to 
determine whether there was a statistically significant 
difference in dose to OARs between these groups. 
 
Results: In the group with IMN treatment, 95% of prescribed 
dose to the IMN PTV covered a median volume of 99% (range 
90-100). There was a significant increase in dose to the RCA 
in the IMN treated group compared to the control group. The 
maximum dose to the RCA (3.33 Gy vs 2.35 Gy, p<0.0001) and 
mean RCA dose (2.41 Gy vs 1.69 Gy, p<0.0001) were both 
increased. Similarly, the mean heart dose (MHD) was 
increased (1.3 Gy vs 1.09 Gy, p<0.022). Inclusion of the IMNs 
increased lung V20 (18 Gy vs 15 Gy, p<0.00021) and mean 
lung dose (9.1 Gy vs 8.09 Gy, p<0.00051). There was a 
significant increase in the volume of contralateral breast 
receiving 3 Gy in the group requiring IMN treatment (3.75 Gy 
vs 0 Gy, p<0.0001). 
 
Conclusion: Inclusion of the IMNs in patients undergoing 
PMRT significantly increases radiation dose to the RCA and 
MHD. An acceptable dose to the RCA has not been well-
established but should be as low as is reasonably achievable. 
The dose and clinical implications of radiation to the RCA 
needs further evaluation in prospective studies utilizing 
techniques to minimize cardiac exposure. 
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Purpose or Objective: To compare radiation dosimetry of 
various cardiac structures and other thoracic tissue, such as 
lung fields and non-treated breast, associated with breast 
irradiation (left versus right-sided) in supine versus prone 
treatment positions. 
 
Material and Methods: Twenty-four post-lumpectomy 
patients (8 left-sided, 16 right-sided) underwent non-contrast 
2mm slice thickness radiotherapy (RT) planning CT scans in 
the supine and prone positions. Optimized tangential breast 
RT plans were generated. In all cases, prescribed RT dose 
was 50Gy in 2Gy daily fractions. Twenty specific structures 
(whole heart, atria and ventricles, major vessels, cardiac 
valves, epicardial coronary arteries including left anterior 
descending (LAD), ipsilateral/contralateral lung and non-
treated breast) were contoured on each CT dataset based on 
a published reference atlas. Maximum, minimum, mean doses 
and volume (cm³) were compared for all structures in both 
supine and prone positions. Whole heart V5, V25 and V30 as 
well as lung V20 were evaluated. The independent two-
sample t-test was used to determine the impact of treatment 
laterality and the paired t-test for the treatment positioning 
on RT dosimetry respectively, with p<0.05 considered 
significant. 
 
Results: Left compared to right-sided breast irradiation 
significantly increased maximum (p<0.001) and mean 
(p<0.001) whole heart dose, as well as doses to individual 
cardiac structures, in both prone and supine positions.  
Prone versus supine positioning significantly increased 
maximum whole heart dose 25.8Gy versus 19.2Gy (p=0.007) 
and mean LAD artery 8.4Gy vs. 5.0Gy respectively (p=0.03). 
Whole heart V5 (3.9 vs. 2.5%), V25 (1.4 vs. 0.8%), and V30 
(1.1 vs. 0.7%), did not differ significantly between prone and 
supine positions. Table 1 illustrates comparisons of other 
individual cardiac structures. As anticipated, maximum dose 
(48.5 vs. 50.3Gy), mean dose (3.3 vs. 6.5Gy) and V20 (5.3% 
vs. 11.5%) to the ipsilateral lung (p<0.001 for all comparisons) 
were reduced when patients were treated in the prone versus 
supine position. 
 
 
Conclusion: A statistically higher radiation dose was seen to 
the whole heart and various cardiac structures, including 
atria, ventricles and LAD artery, for left compared to right-
sided breast cancer patients. Furthermore, prone positioning 
increased maximum whole heart and LAD artery doses, 
despite its known benefit in reducing dose-volume effects to 
lung tissue. This is one of few studies to assess differential 
radiation doses to individual cardiac structures. 
 
Poster: Clinical track: Lung  
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Purpose or Objective: A prognostic model for non-small cell 
lung cancer (NSCLC) patients with validated clinical variables 
[gender, World Health Organization performance status, 
forced expiratory volume in 1 second, number of positive 
lymph node stations, and total gross tumor volume], and 
blood-biomarkers related to hypoxia [osteopontin (OPN) and 
carbonic anhydrase IX (CA-IX)], inflammation [interleukin-6 
(IL-6), IL-8, and C-reactive protein (CRP)], and tumor load 
[carcinoembryonic antigen (CEA), and cytokeratin fragment 
21-1 (Cyfra 21-1)] was developed and validated. Finally, the 
model was extended with alpha-2-macroglobulin (α2M), 
serum interleukin-2 receptor (sIL2r), toll-like receptor 4 
(TLR4), and vascular endothelial growth factor (VEGF). 
 
Material and Methods: The model was developed and 
validated on respectively 182 and 181 inoperable stage I-IIIB 
NSCLC patients treated radically with (chemo)radiotherapy. 
It included the mentioned clinical features, and blood-
biomarkers were selected by least absolute shrinkage and 
selection operator (LASSO). Discrimination was reported by 
means of internal 10-fold cross-validated (CV) and external 
concordance index (c-index). 
 
Results: The inclusion of OPN and Cyfra 21-1 (hazard ratios of 
3.3 and 1.7) in this clinical model significantly increased the 
c-index from 0.66 to 0.70 (10-fold CV=0.64 and 0.67; c-index 
external =0.62 and 0.66). The calibration slope of the 
prognostic index in the validation cohort was 0.66 (p<0.01), 
therefore requiring re-calibration. Further extension of the 
model by selecting from the 4 additional blood biomarkers 
yielded a c-index of 0.67 (10-fold CV = 0.66), TLR4 was left 
unincluded, and resulted in a better fitting model (likelihood 
ratio test: p=0.01; Table 1). Hypoxia is known to be present 
in NSCLC adversely affecting disease progression and 
response to radiation treatment. Likewise, tumor load is 
often associated with disease development and prognosis. 
The value of hypoxia and tumor load associated markers OPN 
and Cyfra 21-1, was confirmed in this study. Extension of the 
model included α2M, sIL2r, and VEGF, with higher 
concentrations of these new markers being associated with a 
worse prognosis. α2M, a previously identified candidate 
predictor for radiation pneumonitis was found to be a 
prognostic factor in NSCLC. IL-2 was already identified as an 
independent prognostic marker in patients with advanced 
NSCLC. The correlation of IL-2 with shorter survival was 
confirmed in these cohorts and may be of relevance for 
patients receiving IL-2 immunotherapy. Finally, VEGF, the 
angiogenesis factor found in a variety of solid tumors 
including NSCLC, was found to be of added value in the 
extended model. 
